Jobs
-
In an effort to continue their leading status of innovation and development, through Four Corners Group, Trudell Medical International is now seeking a Group Director, Science & Technology. THE ROLE This position will be responsible… Read more . . .
-
A Phase 2b study of Aradigm’s inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchietasis has shown a significant reduction in Pseudomonas aeruginosa colony forming units per gram of sputum (CFUs) over a 28-day treatment… Read more . . .
-
Pearl Therapeutics is advancing its PT003 combination inhaler for COPD, and the products individual components, into a new series of Phase 2 trials in patients with moderate-to-severe COPD. The individual compounds are PT001, glycopyrrolate, and… Read more . . .
-
Lamellar Biomedical’s LMS-611, an inhaled Lamellasome, an artificial lamellar body, for the treatment of patients with cystic fibrosis has received orphan drug designation from the European Commission. CF patients’ lungs may be missing lamellar bodies… Read more . . .
-
The “Deep Draw Container Forming Method” developed by Mystic Pharmaceuticals for packaging of intranasal drugs for use with its VersiDoser and VRx2 intranasal delivery systems has been awarded US Patent No. 7,963,089. Both delivery systems… Read more . . .
-
After receiving written guidance from the FDA in late May, says Generex, it has revised its development program for its Oral-lyn buccal insulin spray. A reorganized medical/regulatory group within the company will focus its efforts… Read more . . .
-
Gilead, Seattle, WA. Reporting to the Director, Respiratory Pharmaceutical Development, the successful candidate will play a number of key roles in the development of Gilead’s respiratory products. The successful candidate will be a member of… Read more . . .
-
An article by Johns Hopkins researchers published in the BMJ, the British Medical Journal, suggests that patients using the Respimat tiotropium soft mist inhaler for the treatment of COPD are 52% more likely to die… Read more . . .
-
The UK site where Pfizer has performed inhalation R&D is now on the market as “Discovery Park.” The company announced the closing of the site, which employed 2400 people, in February 2011. Although a representative… Read more . . .
-
According to Perrigo Company, which is partnered with Teva on a generic triamcinolone acetonide nasal spray, Teva has begun shipping the product. Perrigo developed the nasal spray, which is a generic equivalent of Sanofi’s Nasacort… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland